Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2015 05/20/2015 05/21/2015 05/22/2015 05/26/2015 Date
64.21(c) 67.56(c) 67.17(c) 67.76(c) 66.99(c) Last
1 620 402 2 760 025 1 934 802 1 284 341 1 237 800 Volume
-0.19% +5.22% -0.58% +0.88% -1.14% Change
More quotes
Financials ($)
Sales 2015 296 M
EBIT 2015 -24,8 M
Net income 2015 -39,7 M
Finance 2015 376 M
Yield 2015 -
Sales 2016 318 M
EBIT 2016 -34,5 M
Net income 2016 -60,1 M
Finance 2016 531 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 25,8x
EV / Sales 2016 23,5x
Capitalization 8 020 M
More Financials
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery platform.It operates through the Drug Discovery and Development segment which exploits a novel drug discovery platform created to generate a broad pipeline of first-in-class drugs for the company... 
Sector
Biotechnology & Medical Research
Calendar
06/10 | 05:40pmPresentation
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
05/14 ISIS PHARMACEUTICALS : Licenses ISIS-FXI Rx to Bayer to Develop and Commercializ..
05/06 ISIS PHARMACEUTICALS : Earns $10 Million Milestone Payment From Biogen
05/05 ISIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
05/05 ISIS PHARMACEUTICALS : Results of Operations and Financial Condition, Financial ..
05/05 ISIS PHARMACEUTICALS : reports 1Q loss
05/05 ISIS PHARMACEUTICALS : Bayer Licenses ISIS-FXI Rx from Isis Pharmaceuticals to D..
05/05 ISIS PHARMACEUTICALS : Gets $10 Million Milestone Payment from Biogen
05/04 ISIS PHARMACEUTICALS : Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pha..
More news
Sector news : Biotechnology & Medical Research - NEC
07:31a INCYTE : Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2..
05/26DJNew Push Ties Cost of Drugs to How Well They Work
05/26 SYNAGEVA BIOPHARMA : Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL De..
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
05/13 Just What Is Invested Capital Anyway?
05/11 Regeneron Beats, Raises And Accelerates Its Late-Stage Product Development
05/06 ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q1 2015 Results - Earnings Ca..
05/05 Isis Pharma revenues up 122% in Q1
05/05 Isis Pharmaceuticals beats by $0.06, beats on revenue


Comments 
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions